Neurocrine Biosciences Inc (NBIX)

Operating return on assets (Operating ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	570,500	578,800	536,200	464,400	250,900	204,000	150,600	131,700	249,000	109,300	66,000	74,100	102,500	210,600	121,800	135,600	163,000	140,000	274,400	232,200
Total assets	US$ in thousands	3,718,700	3,535,000	3,305,000	3,472,400	3,251,400	2,848,200	2,613,100	2,359,800	2,368,700	2,143,400	2,005,700	2,144,500	2,072,500	2,017,300	1,956,400	1,846,400	1,734,700	1,502,600	1,515,600	1,361,900
Operating ROA		15.34%	16.37%	16.22%	13.37%	7.72%	7.16%	5.76%	5.58%	10.51%	5.10%	3.29%	3.46%	4.95%	10.44%	6.23%	7.34%	9.40%	9.32%	18.11%	17.05%

December 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $570,500K ÷ $3,718,700K
= 15.34%

Neurocrine Biosciences Inc's operating return on assets (operating ROA) has shown fluctuating trends over the given time period. The operating ROA started at a relatively high level of 17.05% in March 31, 2020, and peaked at 18.11% by June 30, 2020. However, there was a notable decline in the operating ROA in the following quarters before reaching a low of 3.29% by June 30, 2022.

Subsequently, there was a gradual recovery in the operating ROA, with the ratio increasing to 16.22% by June 30, 2024. The operating ROA remained relatively stable around the 15-16% range in the latter part of the period, with a slight decrease to 15.34% by December 31, 2024.

Overall, the analysis of Neurocrine Biosciences Inc's operating ROA indicates fluctuations in profitability levels over time, with periods of both growth and decline. It is important for stakeholders to monitor these ratios closely to assess the company's operational efficiency and financial performance.